Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).
Maruyama D, Iida S, Ogawa G, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Nagai H. Maruyama D, et al. Among authors: nagai h. Br J Haematol. 2021 Feb;192(3):531-541. doi: 10.1111/bjh.16878. Epub 2020 Jun 24. Br J Haematol. 2021. PMID: 32583431 Free PMC article. Clinical Trial.
Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.
Kihara R, Watanabe T, Yano T, Uike N, Okamura S, Kawano F, Hanada S, Sunami K, Inoue N, Sawamura M, Yoshida S, Shimomura T, Kitano K, Kojima Y, Horibe K, Nagai H. Kihara R, et al. Among authors: nagai h. Int J Hematol. 2013 Jan;97(1):98-102. doi: 10.1007/s12185-012-1243-2. Epub 2012 Dec 15. Int J Hematol. 2013. PMID: 23243003
Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D, Asano N, Ohmachi K, Kinoshita T, Okamoto M, Maeda Y, Mizuno I, Matsue K, Uchida T, Nagai H, Nishikori M, Nakamura S, Ogura M, Suzuki R. Chihara D, et al. Among authors: nagai h. Br J Haematol. 2015 Sep;170(5):657-68. doi: 10.1111/bjh.13486. Epub 2015 May 7. Br J Haematol. 2015. PMID: 25953436 Free article. Clinical Trial.
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H, Choi I, Hatake K, Uchida T, Nishikori M, Kinoshita T, Matsuno Y, Nishikawa T, Takahara S, Tobinai K. Maruyama D, et al. Among authors: nagai h. Cancer Sci. 2016 Dec;107(12):1785-1790. doi: 10.1111/cas.13076. Epub 2016 Nov 25. Cancer Sci. 2016. PMID: 27616553 Free PMC article. Clinical Trial.
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y, Yamamoto K, Uike N, Tomita A, Nagai H, Kurosawa M, Mori S, Nawano S, Terauchi T, Ohashi Y, Tobinai K. Igarashi T, et al. Among authors: nagai h. Int J Hematol. 2016 Dec;104(6):700-708. doi: 10.1007/s12185-016-2097-9. Epub 2016 Oct 6. Int J Hematol. 2016. PMID: 27714587 Clinical Trial.
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Among authors: nagai h. Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29. Int J Hematol. 2017. PMID: 27900638 Clinical Trial.
2,675 results